Avalo Therapeutics (NASDAQ:AVTX) Upgraded to “Hold” at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Avalo Therapeutics (NASDAQ:AVTX – Free Report) from a sell rating to a hold rating in a research note published on Sunday morning.

Several other research analysts have also issued reports on the company. Leerink Partners initiated coverage on Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 target price for the company. Citigroup restated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Citizens Jmp reduced their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. HC Wainwright decreased their price objective on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a report on Friday, August 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.10.

Check Out Our Latest Analysis on AVTX

Avalo Therapeutics Price Performance

AVTX stock opened at $19.59 on Friday. Avalo Therapeutics has a 1 year low of $8.41 and a 1 year high of $24.27. The company has a market cap of $1.05 billion, a P/E ratio of -4.48 and a beta of 0.80. The firm has a 50-day moving average of $17.82 and a 200 day moving average of $16.43.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, equities research analysts expect that Avalo Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insider Activity at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the sale, the insider directly owned 51,776 shares of the company’s stock, valued at $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVTX. Caligan Partners LP purchased a new position in Avalo Therapeutics in the third quarter worth about $10,592,000. Balyasny Asset Management L.P. purchased a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $10,390,000. Vanguard Group Inc. grew its holdings in shares of Avalo Therapeutics by 314.9% during the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after buying an additional 525,696 shares during the last quarter. Millennium Management LLC increased its position in shares of Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after acquiring an additional 522,548 shares in the last quarter. Finally, Seven Fleet Capital Management LP increased its position in shares of Avalo Therapeutics by 806.0% during the first quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after acquiring an additional 510,540 shares in the last quarter. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

(Get Free Report)

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

Read More